后证治药动学的医药创新——整体导向还原论研究  

Medical Innovation of Post Syndrom and Treatment Pharmacokinetics: A Study on Holism-Guided Reductionism

作　　者：黄熙[1] 任平[1] 

机构地区：[1]中南大学湘雅医院

出　　处：《中医杂志》2013年第5期365-368,共4页Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81173591;81072967);湖南省中西医结合重点学科资助项目;国家中医药管理局中西医结合临床重点学科资助项目

摘　　要：概述了20年来证治药动学的相关研究,即整体导向还原论研究。证治药动学能对方剂的吸收生物活性成分(吸收生物活性成分)定性、定量,生物方剂分析药理能阐明代表方剂疗效的主要吸收生物活性成分。随后研究工作的重心是以方剂吸收生物活性成分为枢纽的药学研究策略及其应用,包括方剂药动学与活性导向分离的研究、疗效相关最佳吸收生物活性成分比例作为方剂质量控制标准的研究及肝气郁结相关抑郁共病机理的研究。方剂吸收生物活性成分及其作用机理的深入研究,有利于开辟一条新药研发与发病机理研究的新途径,还可融合到"组分配伍"的科学研究中。To review the theory and application of the ＂syndrome and treatment pharmacokinetics＂ pharmaceutical innovation in the past twenty years,which is a holismguided reductionism research. ＂syndrome and treatment pharmacokinetics＂ can exam ine the absorbed bioactive compound （ABC） of TCM prescription in vivo through the qualitative and quantitative analysis. Bio ethnopharmaceutical analytical pharmacology （BAP） is an idea for elucidating ABC in traditional Chinese medicine （TCM） for mula or herbal remedy. ABC is focused on as a hub of pharmacy strategy in the subsequent research, including ethnopharmaco kineticand activityguided isolation （EAGI）, as well as researches on ABC to infer the mechanism of depression comorbidity related to liverqi stagnation. The indepth study of ABC and its mechanism is help for opening up a new approach to research drug R＆D and pathogenesis. In addition ,our work can melts the TCM ＂components and combinations＂ together and assist each other in scientific research.

关 键 词：证治药动学 方剂 生物活性成分 整体导向还原论 

分 类 号：R289[医药卫生—方剂学]